Fig. 7.

Scenario analysis of the variation in the drug concentration and IgG concentration with the administration of 150 mg of atacicept weekly for 24 weeks. Pharmacokinetic parameters are defined in Table 1. The treatment schedule and the maximum IgG reduction of up to 40% were obtained from [35]. A Simulated  pharmacokinetics (PK) of 150 mg of atacicept administered weekly for 24 weeks (to mimic the design of the ADDRESS II clinical trial of atacicept). B Simulated dynamics of the safety biomarker IgG for various baseline levels